January 2017 - Cancer Currents Blog
- Less-Frequent Zoledronic Acid Treatment Effective at Preventing Bone Metastasis Complications
In a clinical trial involving patients with metastatic cancer, administration of zoledronic acid every 12 weeks was as effective at preventing skeletal-related events caused by bone metastases as administration every 4 weeks.
- Genome Study Points to New Subtypes of Esophageal Cancer
A new study by The Cancer Genome Atlas Research Network could help classify esophageal cancers according to their genetic and molecular alterations and identify potential new treatment options.
- Shifts Seen in Tobacco Product Types Purchased in US
The consumption of cigarettes, small cigars, and chewing tobacco has declined over the past 15 years, according to a new study. These declines were partially offset by a rise in consumption of large cigars, pipe tobacco, and snuff.
- The Global Economic Burden of Tobacco: An Interview with Dr. Mark Parascandola
NCI’s Dr. Mark Parascandola answers questions about The Economics of Tobacco and Tobacco Control, the latest in a series of monographs on tobacco use and tobacco control, which was co-written with the World Health Organization.
- Ibrutinib Relieves Chronic Graft-Versus-Host Disease Symptoms
The targeted cancer therapy ibrutinib can effectively treat the symptoms of chronic graft-versus-host disease, a common and serious complication of allogeneic stem cell transplants, findings from a small clinical trial show.
- FDA Approves Rucaparib for BRCA-Positive Ovarian Cancer
The FDA has approved rucaparib for women with BRCA-positive advanced ovarian cancer based on findings from two small clinical trials showing that it shrank tumors.
- For Some Breast Cancer Survivors, Drug May Reduce Treatment-Related Joint Pain
Researchers have found that duloxetine (Cymbalta®), a drug most commonly used to treat depression, may also reduce joint pain caused by aromatase inhibitors in some women being treated for early-stage breast cancer.